Skip to main content
Ahead of BioBeat24, Iraida Soria-Espinosa, Senior Innovation & Business Manager at UK DRI, and Miranda Weston-Smith, Founder of BioBeat, caught up with keynote speaker Zoe Kourtzi, Professor of Computation Cognitive Neuroscience, University of Cambridge. BioBeat24:  Driving solutions in neurodegeneration in digital will take place at the Sainsbury Wellcome Centre, London in the afternoon of Thursday 16 May 2024. Zoe, we are thrilled you are delivering the keynote, why is finding solutions for dementia so important for you? Zoe: The statistics about dementia are overwhelming: over…
Mark your calendars with the various opportunities to network and learn about the sector by registering for the events below. Further details for all events can be found by clicking the hyperlinks. The One Nucleus events calendar changes and updates regularly; the best place to keep up to date is via our website. To help you decide why you should attend, below we have shared some of the learnings from our events so far this year. In February, at the London Bioscience Innovation Centre, we learnt about how antimicrobial resistance, zoonotic diseases, food safety, and climate change are all…
by Alicia Gailliez, Business Development Manager, One Nucleus  Securing funding is always a top challenge for biotech companies. This blog will discuss how the uncertainty in the biotech funding landscape may be transforming into more positive tones as we see Nasdaq IPOs happening and private investment rounds returning. Amid this optimistic news, we celebrate some case studies of investment raised by One Nucleus members, highlighting some of the ways that One Nucleus helps to support our members to scale their innovation and businesses, often in a challenging environment. The global…
So you think buying cyber insurance means your business will avoid a major nightmare? You’ve bought a cyber insurance policy to help protect your company against devastating cyber-attacks. It looks comprehensive so you can finally sleep at night. But before you get too carried away, is that really the case? Many companies which have been victims of a cyber-attack held cyber insurance policies. That cyber insurance did not prevent them from being the next victim. Of course, you will be glad you had the policy if the worst does happen, but it is essential to understand the difference between…
Report from the Genesis Fringe Event held on 6 December 2023 by Tony Jones For the past decade, a number of satellite sessions have been held across London and online as part of the build up to the annual Genesis Conference which has been a key fixture in the life science calendar for over twenty years. With sessions that vary in size, content, topic focus and exclusivity, the Genesis Fringe, which is described further in the Genesis Review/One Nucleus at BIO-Europe Spring 2023 publication launched in March, forms an informal London Life Science Week. The Fringe affords participants access to…
By Tony Jones, CEO, One Nucleus On the evening of 21 March 2024 at No. 11 Cavendish Square in London, for the first time in its history, One Nucleus delivered an Annual Awards Dinner to recognise and celebrate the breadth and depth of excellence within the One Nucleus network.   One Nucleus sees itself as a very inclusive not-for-profit membership organisation for life science companies, seeking to support all connected organisations on their journey to success irrespective of size, business model, stage of development, or geography. It is One Nucleus’s firm belief that a successful…
By Alicia Gailliez, Business Development Manager, One Nucleus The ON Helix session ‘New Horizons in Biomarker Technologies’ will look at the innovations that have the potential for earlier diagnosis and precision treatment across a wide range of diseases.  The results of a recent study offering potential for early detection of Alzheimer’s’ disease offered a good exemplification of the possible. Researchers found that looking for a specific protein in blood called p-tau217 to be highly accurate in detecting the disease. These results could have a significant impact on screening for…